Molplex and Enamine today announced a new partnership to offer the Enamine screening collection of 1.8 million stock chemicals through the Molplex online drug design and assay-ready chemical supply services. The agreement is a major step towards eliminating the high start-up costs ofdrug discovery, bringing sophisticated drug design, compound management and assay-ready chemistry to the world’s drug discovery scientists on demand. The agreement adds Molplex online drug design systems to the deep experience in organic chemistry and compound management of Enamine to solve the problem of generating viable chemical leads for novel targets.

Molplex CEO David E. Leahy said: “We are very proud to be selected by Enamine as their partner for on demand drug discovery services at a time when major restructuring of the industry is creating new opportunities and new markets for our combined expertise. This agreement marks a step change in the size and scope of our assay-ready chemical supply service and major progress towards our goal of being the world’s first choice partner for enabling the long tail of drug discovery”

Enamine Chief Marketing and Sales Officer Dr Vladimir Ivanov said “We are happy to partner with Molplex and supply our products to the highly integrated drug discovery platform they maintain. In this collaboration we deploy all our discovery resources including the world’s biggest screening collection (1.8 million compounds), largest inventory of building blocks (45,000 products), and over 300 chemists at our Kiev’s site to assure high cost efficiency and high responsiveness to any follow up chemistry emerging from projects run through Molplex discovery platform.”

Via EPR Network
More Biotech press releases